Adarx Pharmaceuticals, Inc.
Clinical trials sponsored by Adarx Pharmaceuticals, Inc., explained in plain language.
-
Silencing the gene: new trial aims to stop debilitating swelling attacks
Disease control Recruiting nowThis study is testing a new drug called ADX-324 to see if it can prevent the sudden, painful swelling attacks caused by hereditary angioedema (HAE). It will involve about 90 adults with HAE who will receive either the drug or a placebo. The main goal is to see if the drug reduces…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New shot aims to halt blinding eye disease
Disease control Recruiting nowThis study is testing if a new medicine called ADX-038, given as an injection under the skin, can slow down the progression of geographic atrophy. Geographic atrophy is a severe form of age-related macular degeneration that causes permanent blind spots in central vision. The tria…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets rare kidney diseases
Disease control Recruiting nowThis study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The go…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human test of new Blood-Clotting drug begins
Knowledge-focused Recruiting nowThis is the first study to test ADX-626 in people. Researchers will give the drug to 44 healthy adults to check if it's safe and how the body processes it. They'll also measure how it affects certain blood clotting factors.
Phase: PHASE1 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC